Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

REMS Strength Driven More By Drug’s Benefits Than Risks, FDA Suggests

Nov 05 2012

• By Martin Berman-Gorvine

Related Content

Teratogenic Drugs Need Better Risk Plans; FDA Seeks Advice From Advisory Cmte.

Nov 05 2012

REMS For <em>Qsymia</em> Limits Distribution, But Vivus To Explore Expanding Access

Jul 23 2012

FDA Repeats Birth-Defect Risk With Roche, Novartis Transplant Drugs

May 16 2008

Related Companies

Novartis AG

Genentech, Inc.

Vivus, Inc.

Additional Topics

United States Safety Risk Management BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window